Covidien (Dublin, Ireland) reported the completion of enrollment in its DEFINITIVE AR (anti-restenosis) study. As the third study in the DEFINITIVE trial series, this randomized pilot is designed to address the challenge of preventing restenosis, the re-narrowing of a blood vessel following treatment, a common occurrence in patients with peripheral artery disease (PAD). Read More
